Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: Results of CALGB 89803

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5777-5787

  Warren, Robert S ^a   Atreya, Chloe E ^a   Niedzwiecki, Donna ^b   Weinberg, Vivian K ^a   Donner, David B ^a   Mayer, Robert J ^c   Goldberg, Richard M ^d   Compton, Carolyn C ^e   Zuraek, Marlene B ^a   Ye, Cynthia ^b   Saltz, Leonard B ^f   Bertagnolli, Monica M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PROTEIN P53; ZINC;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA BINDING; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL RATE; TP53 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEOPLASM STAGING; PROTEIN BINDING; SEX FACTORS; TUMOR SUPPRESSOR PROTEIN P53; ZINC;

EID: 84886407775     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0351     Document Type: Article

References (39)

1. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
2. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
3. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-44.
4. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23: 7518-28.
5. Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, et al. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 2004;210:101-9.
6. Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006;17:842-7.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
8. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
9. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
10. Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006;6:83-90.
11. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
12. Russo A, Migliavacca M, Zanna I, Valerio MR, Latteri MA, Grassi N, et al. p53 mutations in L3-loop zinc-binding domain, DNAploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up. Cancer Epidemiol Biomarkers Prev 2002;11: 1322-31.
13. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
14. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
15. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998;4:203-10.
16. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-5.
17. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-61.
18. Drmanac S, Kita D, Labat I, Hauser B, Schmidt C, Burczak JD, et al. Accurate sequencing by hybridization for DNA diagnostics and individual genomics. Nat Biotechnol 1998;16:54-8.
19. BertagnolliMM,Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814-21.
20. Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, et al. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer 2012;131:1169-78.
21. Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 2006;66:8287-92.
22. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26: 1317-23.
23. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009;15:6391-7.
24. WichmannMW,Muller C, Hornung HM, Lau-Werner U, Schildberg FW. Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 2001;88:1092-8.
25. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 2003; 90:711-5.
26. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-50.
27. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006;24:3562-9.
28. Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 2011;225:475-8.
29. Zupnick A, Prives C. Mutational analysis of the p53 core domain L1 loop. J Biol Chem 2006;281:20464-73.
30. Menendez D, Inga A, Resnick MA. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci U S A 2010; 107:1500-5.
31. Laghi L, Malesci A. Microsatellite instability and therapeutic consequences in colorectal cancer. Dig Dis 2012;30:304-9.
32. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with metaanalysis. Eur J Cancer 2009;45:1890-6.
33. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011;103:863-75.
34. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15:7322-9.
35. Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153-62.
36. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27: 3117-25.
37. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
38. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25: 2198-204.
39. Institute of Medicine of the National Academies of Sciences. Sexspecific reporting of scientific research: a workshop summary. Washington, DC, 2012.